Biliary Tract Cancer Drug Pipeline — PatSnap Eureka
Biliary Tract Cancer Drug Pipeline: FGFR2, Immunotherapy & Emerging Targets
FGFR2 fusions, PD-1/PD-L1 combinations, and novel biomarkers are reshaping the biliary tract cancer treatment landscape. Explore the patent-driven innovation signals powering next-generation BTC therapies with PatSnap Eureka.
BTC Drug Pipeline: Key Therapeutic Strategies
Biliary tract cancer is a molecularly heterogeneous malignancy. Patent filings from 2018–2025 reveal a multi-pronged drug development landscape spanning covalent FGFR2 inhibitors, antibody biologics, immunotherapy combinations, and emerging epigenetic and multikinase approaches.
Covalent & Competitive FGFR Inhibitors
Futibatinib (TAS-120) by Taiho Pharmaceutical is a selective, irreversible covalent FGFR1/2/3 inhibitor addressing cholangiocarcinoma patients with FGFR2 fusions and co-occurring driver gene mutations including TP53, BAP1, ARID1A, and MYC. Erdafitinib (JNJ-42756493) by Janssen Pharmaceutica NV is a pan-FGFR tyrosine kinase inhibitor documented across TW, JP, CA, and CN jurisdictions for FGFR2 fusion-positive solid tumors.
Polyclonal resistance → covalent inhibition rationaleAnti-FGFR2 Antibodies & ECD Fusion Proteins
Five Prime Therapeutics (now Amgen) holds multiple Israeli patents on anti-FGFR2-IIIb isoform-selective antibodies and FGFR2 extracellular domain fusion proteins for cholangiocarcinoma and gastric cancer. These biologics target the epithelial isoform of FGFR2 and are proposed in combination with PD-1/PD-L1 inhibitors, representing a complementary approach to small-molecule kinase inhibition.
Anti-FGFR2-IIIb isoform selectivityAnti-PD-1/PD-L1 + Chemotherapy Backbone
Jiangsu Hengrui Medicine holds CN patents on anti-PD-1 antibody combined with gemcitabine plus oxaliplatin (GemOX) for malignant BTC. AstraZeneca AB holds a 2025 Brazil patent on durvalumab (anti-PD-L1) plus chemotherapy in BTC. Merck Patent GmbH holds IL and JP patents on a bifunctional anti-PD-L1/TGF-β trap fusion protein covering both treatment-naïve and second-line BTC patients across all four BTC subtypes.
TGF-β co-inhibition: next-generation IO strategyHDAC Inhibition, CDK4/6 Combinations & Multikinase Strategies
Karus Therapeutics holds a WO patent on HDAC inhibitors specifically for BTC — a small-molecule epigenetic intervention. G1 Therapeutics proposes CDK4/6 inhibitor combined with FGFR inhibitor for FGFR-dysregulated cancers, potentially overcoming cell-cycle bypass resistance. Transthera Sciences (Nanjing) holds a JP patent on a multikinase inhibitor targeting Aurora Kinase A upregulation in cholangiocarcinoma.
Aurora Kinase A: emerging kinase target in CCAFGFR2 Fusions: The Core Actionable Target in Intrahepatic Cholangiocarcinoma
The most consistently referenced target across retrieved patent filings is FGFR2 and its oncogenic fusion products. At least 15 distinct FGFR2 fusion partners have been implicated in cholangiocarcinoma or proposed as diagnostic selection criteria, including FGFR2-BICC1, FGFR2-TACC3, FGFR2-KIAA1598, FGFR2-NOL4, FGFR2-TXLNA, FGFR2-KCTD1, FGFR2-CCDC102A, FGFR2-ENOX1, FGFR2-GPHN, and FGFR2-RANBP2.
The therapeutic rationale — inhibition of constitutively activated FGFR2 kinase signaling driving tumor proliferation — is supported by patent claims and referenced academic evidence including Goyal et al. (Cancer Discovery, 2017), cited within the Taiho futibatinib filing. Polyclonal secondary FGFR2 mutations driving acquired resistance to FGFR inhibitors are referenced as a key clinical challenge, motivating next-generation covalent inhibitor strategies such as futibatinib.
Foundation Medicine holds the largest BTC-specific patent cluster in this dataset, with multiple active US patents on FGFR2 and NTRK1 rearrangement-based cholangiocarcinoma treatment methods. Their filings cover Stage I–IV intrahepatic and Stage 0–IV extrahepatic cholangiocarcinoma, implying clinical deployment of companion diagnostic testing across all disease stages. According to the NCI, FGFR2 fusions occur in approximately 10–16% of intrahepatic cholangiocarcinoma cases.
A Japanese filing from LSIP Fund Operating LLC describes detection of novel FGFR2 driver fusions — FGFR2-TXLNA, FGFR2-KCTD1, and FGFR2-BICC1 type 2 — as responsible mutations in biliary tract cancer, providing a companion diagnostic framework for identifying patients eligible for FGFR2-targeted therapy.
BTC Pipeline: Key Patent Data Visualised
Patent signals from the PatSnap Eureka dataset reveal the clinical benchmarks, combination strategies, and assignee activity shaping the biliary tract cancer drug development landscape.
ABC-02 Trial Benchmark: Median Overall Survival in BTC
Gemcitabine/cisplatin (11.7 months) vs gemcitabine alone (8.1 months) — the first-line standard cited in Jiangsu Hengrui patent filings as the benchmark for PD-1 + GemOX combination strategies.
BTC Combination Strategy Patent Activity
Number of distinct combination approaches documented in the BTC patent dataset, showing immunotherapy-based combinations as the most active development zone.
Beyond FGFR2: Immunotherapy Combinations & Novel Biomarkers
Multiple retrieved patents identify PD-1/PD-L1 immune checkpoint evasion as central to BTC biology, with TGF-β co-signalling and novel targets expanding the actionable landscape.
Anti-PD-L1/TGF-β Bifunctional Trap (Merck Patent GmbH)
Merck Patent GmbH holds IL and JP patents on a bifunctional anti-PD-L1/TGF-β trap fusion protein for BTC — designed to inhibit both membrane-bound PD-L1 (predominantly at tumor sites) and soluble TGF-β (in blood and stroma). Coverage spans treatment-naïve patients and those who failed or are intolerant to first-line chemotherapy, explicitly naming intrahepatic and extrahepatic cholangiocarcinoma, carcinoma of the ampulla of Vater, and gallbladder cancer.
Anti-PD-1 + GemOX Chemotherapy Backbone (Jiangsu Hengrui)
Jiangsu Hengrui Medicine holds two CN patents on anti-PD-1 antibody combined with gemcitabine plus oxaliplatin (GemOX) for malignant biliary tract tumors. These filings reference EGFR pathway gene abnormalities (EGFR, KRAS, BRAF, PI3KCA) as characteristic of the BTC molecular landscape and cite the ABC-02 Phase III trial benchmark as the clinical standard being improved upon.
IP Strategy & Competitive Landscape Signals
Patent filings from 2018–2025 reveal a layered IP landscape with significant implications for drug developers, diagnostics companies, and research institutions entering the BTC space.
FGFR2 Fusion Detection IP Is a Strategic Battleground
Foundation Medicine holds multiple active US patents on FGFR2/NTRK1 rearrangement-based cholangiocarcinoma treatment methods, while Taiho (futibatinib), Janssen (erdafitinib), and Five Prime (antibody-based) hold complementary therapeutic IP. Drug developers entering this space should assess freedom-to-operate across this layered IP landscape, particularly regarding companion diagnostic claims. The PatSnap Analytics platform enables rapid IP landscape mapping.
Layered CDx + therapeutic IPCovalent FGFR Inhibition Differentiated by Resistance Profile
The Taiho futibatinib patent explicitly addresses cholangiocarcinoma patients with co-occurring driver gene mutations alongside FGFR2 fusions. Referenced clinical literature documents polyclonal resistance mutations as a key clinical challenge. Irreversible covalent inhibitors (futibatinib) represent a mechanistic response to this resistance mechanism, differentiating them from competitive inhibitors such as pemigatinib and erdafitinib. For deeper context, NEJM published the ABC-02 trial establishing the first-line benchmark.
Polyclonal resistance → covalent inhibitor rationaleChinese Pharmaceutical Firms Are Active BTC IP Contributors
Jiangsu Hengrui Medicine (PD-1 + chemotherapy), Transthera Sciences Nanjing (multikinase inhibitors), and Shanghai institutional filers (PPDPF) collectively represent growing Chinese domestic patent activity in BTC — a signal of increasing competition in this therapeutic space from Asian-based developers. Janssen Pharmaceutica NV has also filed across TW, JP, CA, and CN jurisdictions for erdafitinib. Review PatSnap's global IP database for jurisdiction-level analysis.
CN, JP, TW, CA, IL, US, WO filings documentedNovel Targets Represent Future Licensing & Partnership Candidates
Preclinical patent filings on PPDPF (Shanghai Chest Hospital) and XPO7/SLK (NIH) signal that academic and government institutions are expanding the BTC target landscape beyond FGFR2 and immune checkpoints. Aurora Kinase A upregulation in cholangiocarcinoma, referenced in the Transthera Sciences filing, represents an emerging kinase target. These could represent future licensing opportunities or early-stage partnership candidates. The PatSnap Life Sciences solution supports target identification and partnership scouting.
PPDPF · XPO7/SLK · Aurora Kinase ATrack BTC Patent Filings in Real Time
Monitor new FGFR2, PD-1/PD-L1, and emerging target filings as they publish globally.
Biliary Tract Cancer Drug Pipeline — key questions answered
Retrieved results document at least 15 distinct FGFR2 fusion partners implicated in cholangiocarcinoma, including FGFR2-BICC1, FGFR2-TACC3, FGFR2-KIAA1598, FGFR2-NOL4, FGFR2-TXLNA, FGFR2-KCTD1, FGFR2-CCDC102A, FGFR2-ENOX1, FGFR2-GPHN, and FGFR2-RANBP2.
Futibatinib (TAS-120) by Taiho Pharmaceutical is a selective, irreversible (covalent) FGFR1/2/3 inhibitor designed to address polyclonal secondary FGFR2 mutations driving acquired resistance. Erdafitinib (JNJ-42756493) by Janssen Pharmaceutica NV is a pan-FGFR tyrosine kinase inhibitor (competitive/reversible) used across multiple FGFR2 fusion-positive tumor types including cholangiocarcinoma.
Foundation Medicine, Inc. holds the largest BTC-specific patent cluster in this dataset, with multiple active US patents on FGFR2/NTRK1-based cholangiocarcinoma treatment methods. Other major assignees include Taiho Pharmaceutical (futibatinib), Janssen Pharmaceutica NV (erdafitinib), Five Prime Therapeutics (anti-FGFR2 antibodies), Merck Patent GmbH (anti-PD-L1/TGF-β trap), AstraZeneca AB, and Jiangsu Hengrui Medicine.
Jiangsu Hengrui Medicine filings cite the ABC-02 Phase III trial as the established first-line benchmark: gemcitabine/cisplatin achieved a median OS of 11.7 months versus 8.1 months for gemcitabine alone. This benchmark contextualises the PD-1 antibody plus GemOX combination as an improvement strategy.
Emerging biomarkers include PPDPF (Pancreatic Progenitor Cell Differentiation and Proliferation Factor), identified by Shanghai Chest Hospital as significantly upregulated in cholangiocarcinoma tissue and associated with poor prognosis in 80 patient specimens; XPO7 (exportin 7) cytoplasmic accumulation, identified by the NIH as predictive of poor outcomes in bile duct cancer; and Aurora Kinase A upregulation, referenced by Transthera Sciences as associated with reduced progression-free and overall survival in cholangiocarcinoma.
Key combination strategies include: FGFR2 inhibitor plus PD-1/PD-L1 inhibitor (Five Prime Therapeutics, Janssen); FGFR inhibitor plus CDK4/6 inhibitor (G1 Therapeutics); anti-PD-L1/TGF-β bifunctional trap (Merck Patent GmbH); anti-PD-1 antibody plus gemcitabine plus platinum chemotherapy (Jiangsu Hengrui); and HDAC inhibition as a standalone or combination epigenetic strategy (Karus Therapeutics).
Still have questions about the BTC drug pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About BTC PatentsAccelerate Your BTC Drug Pipeline Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across oncology, FGFR2 inhibitors, immunotherapy, and beyond.
References
- Treating cancer in patients with co-occurring genetic alterations in FGFR2 and cancer driver genes — Taiho Pharmaceutical Co., Ltd., 2024, JP [Patent]
- Methods of treating cholangiocarcinoma — Foundation Medicine, Inc., 2025, US [Patent]
- Methods of treating cholangiocarcinoma — Foundation Medicine, Inc., 2023, US [Patent]
- FGFR tyrosine kinase inhibitors for the treatment of advanced solid tumors — Janssen Pharmaceutica NV, 2023, TW [Patent]
- FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment — Five Prime Therapeutics, Inc., 2018, IL [Patent]
- Anti-FGFR2 Antibody Combination with Chemotherapeutic Agents in Cancer Treatment — Five Prime Therapeutics, Inc., 2024, CN [Patent]
- Novel therapeutic target fusion gene of biliary tract cancer — LSIP Fund Operating LLC, 2018, JP [Patent]
- Use of Anti-PD-1 Antibody, Gemcitabine and Platinum Drugs in the Treatment of Malignant Biliary Tract Tumors — Jiangsu Hengrui Medicine Co., Ltd., 2019, CN [Patent]
- Dosing regimens for targeted TGF-β inhibition for use in treating biliary tract cancer — Merck Patent GmbH, 2021, IL [Patent]
- Treatment methods for biliary tract cancer using anti-PD-L1 antibodies in combination with chemotherapy — AstraZeneca AB, 2025, BR [Patent]
- HDAC inhibitors for use in the therapy of biliary tract cancers — Karus Therapeutics Ltd., 2021, WO [Patent]
- Novel uses of multikinase inhibitors — Transthera Sciences (Nanjing), Inc., 2025, JP [Patent]
- Methods for treating bile duct cancers with tivozanib — The United States of America, as represented by the Secretary (NIH), 2023, WO [Patent]
- Targeted treatment of cancers with dysregulated fibroblast growth factor receptor signaling — G1 Therapeutics, Inc., 2022, SG [Patent]
- ABC-02 Phase III Trial: Gemcitabine plus Cisplatin vs Gemcitabine Alone in BTC — New England Journal of Medicine, 2010
- National Cancer Institute — Bile Duct Cancer (Cholangiocarcinoma) Treatment Information
- World Health Organization — International Classification of Diseases: Biliary Tract Malignancies
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.